Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Ann Rheum Dis ; 81(10): 1453-1464, 2022 10.
Article in English | MEDLINE | ID: mdl-35868845

ABSTRACT

OBJECTIVES: To test the hypothesis that ROSAH (retinal dystrophy, optic nerve oedema, splenomegaly, anhidrosis and headache) syndrome, caused by dominant mutation in ALPK1, is an autoinflammatory disease. METHODS: This cohort study systematically evaluated 27 patients with ROSAH syndrome for inflammatory features and investigated the effect of ALPK1 mutations on immune signalling. Clinical, immunologic and radiographical examinations were performed, and 10 patients were empirically initiated on anticytokine therapy and monitored. Exome sequencing was used to identify a new pathogenic variant. Cytokine profiling, transcriptomics, immunoblotting and knock-in mice were used to assess the impact of ALPK1 mutations on protein function and immune signalling. RESULTS: The majority of the cohort carried the p.Thr237Met mutation but we also identified a new ROSAH-associated mutation, p.Tyr254Cys.Nearly all patients exhibited at least one feature consistent with inflammation including recurrent fever, headaches with meningeal enhancement and premature basal ganglia/brainstem mineralisation on MRI, deforming arthritis and AA amyloidosis. However, there was significant phenotypic variation, even within families and some adults lacked functional visual deficits. While anti-TNF and anti-IL-1 therapies suppressed systemic inflammation and improved quality of life, anti-IL-6 (tocilizumab) was the only anticytokine therapy that improved intraocular inflammation (two of two patients).Patients' primary samples and in vitro assays with mutated ALPK1 constructs showed immune activation with increased NF-κB signalling, STAT1 phosphorylation and interferon gene expression signature. Knock-in mice with the Alpk1 T237M mutation exhibited subclinical inflammation.Clinical features not conventionally attributed to inflammation were also common in the cohort and included short dental roots, enamel defects and decreased salivary flow. CONCLUSION: ROSAH syndrome is an autoinflammatory disease caused by gain-of-function mutations in ALPK1 and some features of disease are amenable to immunomodulatory therapy.


Subject(s)
Hereditary Autoinflammatory Diseases , NF-kappa B , Protein Kinases/genetics , Amyloidosis , Animals , Cohort Studies , Gain of Function Mutation , Hereditary Autoinflammatory Diseases/genetics , Humans , Inflammation/genetics , Mice , Mutation , NF-kappa B/genetics , NF-kappa B/metabolism , Protein Kinases/metabolism , Quality of Life , Serum Amyloid A Protein , Syndrome , Tumor Necrosis Factor Inhibitors
2.
Am J Med Genet A ; 167A(10): 2366-74, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26061759

ABSTRACT

We report on clinical, genetic and metabolic investigations in a family with optic neuropathy, non-progressive cardiomyopathy and cognitive disability. Ophthalmic investigations (slit lamp examination, funduscopy, OCT scan of the optic nerve, ERG and VEP) disclosed mild or no decreased visual acuity, but pale optic disc, loss of temporal optic fibers and decreased VEPs. Mitochondrial DNA and exome sequencing revealed a novel homozygous mutation in the nuclear MTO1 gene and the homoplasmic m.593T>G mutation in the mitochondrial MT-TF gene. Muscle biopsy analyses revealed decreased oxygraphic Vmax values for complexes I+III+IV, and severely decreased activities of the respiratory chain complexes (RCC) I, III and IV, while muscle histopathology was normal. Fibroblast analysis revealed decreased complex I and IV activity and assembly, while cybrid analysis revealed a partial complex I deficiency with normal assembly of the RCC. Thus, in patients with a moderate clinical presentation due to MTO1 mutations, the presence of an optic atrophy should be considered. The association with the mitochondrial mutation m.593T>G could act synergistically to worsen the complex I deficiency and modulate the MTO1-related disease.


Subject(s)
Cardiomyopathies/genetics , Carrier Proteins/genetics , Homozygote , Intellectual Disability/genetics , Mutation , Optic Nerve Diseases/genetics , RNA, Transfer, Phe/genetics , Adult , Cardiomyopathies/complications , Cardiomyopathies/diagnosis , Cardiomyopathies/pathology , DNA Mutational Analysis , Electron Transport Complex I/genetics , Electron Transport Complex II/genetics , Electron Transport Complex III/genetics , Electron Transport Complex IV/genetics , Female , Gene Expression , Humans , Intellectual Disability/complications , Intellectual Disability/diagnosis , Intellectual Disability/pathology , Male , Membrane Potential, Mitochondrial/genetics , Middle Aged , Mitochondria/metabolism , Mitochondria/pathology , Optic Disk/metabolism , Optic Disk/pathology , Optic Nerve Diseases/complications , Optic Nerve Diseases/diagnosis , Optic Nerve Diseases/pathology , Pedigree , RNA-Binding Proteins , Visual Acuity
3.
Eur J Ophthalmol ; 22(2): 254-8, 2012.
Article in English | MEDLINE | ID: mdl-21623591

ABSTRACT

PURPOSE: Wolfram syndrome (WS) or diabetes insipidus, diabetes mellitus, optic atrophy, and deafness (DIDMOAD) (OMIM 222300) is an inherited neurodegenerative disease characterized by diabetes mellitus and optic atrophy as the 2 major criteria, followed later in life by deafness, diabetes insipidus, and various signs of neurologic impairment. The presence of a cataract has been variably mentioned in WS. METHOD: Two members of a family had thorough ophthalmic examination and their DNA was screened for mutations in mitochondrial DNA, WFS1, OPA1, and OPA3 genes. RESULTS: We report a patient who first had surgery for bilateral cataract at age 5 and who subsequently presented typical signs of WS, i.e., diabetes mellitus, optic atrophy with reduced visual acuity at 20/400 on both eyes at age 22, and mild deafness. The patient was found to be a compound heterozygote for 2 truncating mutations in WFS1, the major WS gene. She carried the previously reported c.1231_1233 delCT and a novel c.2431_2465dup35 mutation. She also was heterozygote for a novel OPA1 sequence variant, c.929A>G in exon 9, whose pathogenicity remains uncertain. The patient's mother was a heterozygous carrier of the c.2431_2465dup35 mutation. She did not have diabetes mellitus or optic atrophy but had bilateral polar cataract. She did not carry the OPA1 sequence variant. CONCLUSIONS: Cataract could be a marker for the WFS1 heterozygosity in this family, namely the c.2431_2465dup35 mutation.


Subject(s)
Cataract/genetics , Membrane Proteins/genetics , Mutation , Wolfram Syndrome/genetics , Adult , Cataract/diagnosis , Cataract Extraction , DNA, Mitochondrial/genetics , Evoked Potentials, Visual/physiology , Exons/genetics , Female , GTP Phosphohydrolases/genetics , Genetic Markers , Heterozygote , Humans , Pedigree , Phenotype , Proteins/genetics , Visual Acuity/physiology , Visual Fields/physiology , Wolfram Syndrome/diagnosis , Wolfram Syndrome/physiopathology , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL